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Proton MRS (1H MRS) provides noninvasive, quantitative metabolite profiles of
tissue and has been shown to aid the clinical management of several brain diseases.
Although most modern clinical MR scanners support MRS capabilities, routine use is
largely restricted to specialized centers with good access to MR research support.
Widespread adoption has been slow for several reasons, and technical challenges
toward obtaining reliable good‐quality results have been identified as a contributing factor. Considerable progress has been made by the research community to address many of
these challenges, and in this paper a consensus is presented on deficiencies in widely
available MRS methodology and validated improvements that are currently in routine
use at several clinical research institutions. In particular, the localization error for the
PRESS localization sequence was found to be unacceptably high at 3 T, and use of the
semi‐adiabatic localization by adiabatic selective refocusing sequence is a recommended
solution. Incorporation of simulated metabolite basis sets into analysis routines is recommended for reliably capturing the full spectral detail available from short TE acquisitions. In addition, the importance of achieving a highly homogenous static magnetic field
(B0) in the acquisition region is emphasized, and the limitations of current methods and
hardware are discussed. Most recommendations require only software improvements,
greatly enhancing the capabilities of clinical MRS on existing hardware. Implementation
of these recommendations should strengthen current clinical applications and advance
progress toward developing and validating new MRS biomarkers for clinical use.
KEYWORDS
brain, consensus, metabolites, MRS, semi‐LASER, shimming
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IN T RO D U C T ION

Proton MRS (1H MRS) has provided a noninvasive measure
of brain metabolites since the late 1980s. Abnormal metabolism is often closely linked to disease processes; therefore,
MRS may improve clinical diagnosis, treatment effect monitoring, and understanding of disease mechanisms.1 However,
widespread clinical adoption has been slow, with MRS being
used primarily in specialized imaging centers.
Increased availability of 3T MR scanners in hospitals
presents an important opportunity for MRS, as metabolite levels are more reliably measured than at 1.5 T due to
reduced spectral overlap and an improved SNR (Figure 1).2
However, additional challenges are associated with 3T
MRS compared with 1.5 T. Reduced homogeneity of the
static magnetic field (B0) at 3 T results in broadened spectral linewidths and degraded spectral quality; therefore,
improvements in hardware and methodology for optimizing
the B0 homogeneity over the region for MRS are necessary.
Metabolite localization errors, known as chemical shift displacement (CSD), also increase at 3 T, requiring optimized
RF pulse shapes and higher B1 RF power to compensate.
Recent progress in the research community has addressed
these challenges, but a major disparity remains between
what is available for research and for routine clinical applications. In addition, the wide range of MRS sequences,
parameters, and analysis choices can make the technique
particularly difficult for nonexpert users.
This paper was written and agreed upon by 49 MRS
experts who belong to the International Society for Magnetic
Resonance in Medicine (ISMRM) MRS study group with the
following aims:
1. Recommend appropriate methodology to improve the
quality of future MRS studies and increase MRS standardization, to facilitate clinical trials and meta‐analyses
of MRS efficacy;
2. Provide recommendations to vendors regarding the best
MRS implementations and practices; and
3. Focus the research community on resolving key technical
barriers that have delayed wider clinical adoption of MRS.
Following initial discussions, an online survey was
designed and completed by the group, and the results
(Supporting Information Section A) were used to guide further discussions leading to our final consensus and recommendations. We restricted our scope to 1H MRS detection
of endogenous brain metabolites, using currently available
methodologies that we believe are ready for incorporation
into clinical scanner platforms. We first present a basic
introduction to 1H MRS methodology that is designed
to give newcomers to 1H MRS sufficient background to
understand the subsequent consensus sections.

F I G U R E 1 An adult low‐grade glioma brain tumor spectrum
acquired at 3 T with PRESS single‐voxel spectroscopy (SVS)
localization, 18‐mm‐sided cubic voxel, 128 averages, TE = 32 ms,
and TR = 2 seconds. Parametric fitting was performed with the
TARQUIN algorithm35 using a simulated basis set of metabolite,
lipid, and macromolecule signals. Although a greater level of spectral
detail is available when compared with 1.5 T, particularly for strongly
J‐coupled metabolites such as glutamate and myo‐inositol, data quality
is highly dependent on achieving good shimming. For this example,
a metabolite FWHM of 0.03 ppm and SNR of 83 were achieved, in
which the FWHM was measured from the highest metabolite signal
(total choline [tCho] = glycerophosphocholine + phosphorylcholine)
following baseline subtraction. The SNR was calculated as the ratio
between the highest baseline subtracted, metabolite signal intensity,
and 2 times the SD of the noise level estimated from a spectral region
free from metabolite signals

2 | STANDARD M RS
M ETHODOLOGY
2.1

|

Single‐voxel spectroscopy

Proton single‐voxel spectroscopy (SVS) is relatively simple
to plan and yields clinically informative results, with robust
acquisition procedures available on all commercial systems.
Single‐voxel spectroscopy is currently the most commonly
used method to acquire spectra from a single volume of
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interest (VOI or voxel). Generally, a 5‐minute acquisition
time provides good‐quality spectra at 3 T from tissue volumes down to 4 cm3, assuming that good B0 homogeneity
can be achieved. We briefly outline the main technical considerations for widely available SVS methodology.

2.1.1

|

Acquisition methods

Stimulated echo acquisition mode (STEAM)3,4 and point‐
resolved spectroscopy (PRESS)5 are used widely to provide single‐shot 3D localization from the intersection of 3
slices. In STEAM, 3 slice‐selective RF pulses, each with
90° flip angles, produce a stimulated echo with typically a
shortest TE of approximately 20 ms. In PRESS, a 90° excitation pulse combined with 2 refocusing pulses produce a
spin echo with a shortest TE of approximately 30 ms. The
PRESS refocusing pulses are nominally 180°; however,
some implementations use lower flip angles. Shorter TEs
are possible for both STEAM and PRESS, but we restrict
this section to commercial implementations. The PRESS
technique is more commonly used, as its spin echo provides twice the signal compared with the STEAM stimulated echo.
Because multiple averages are typically measured for
SVS, the phase of the RF pulses and receiver may be cycled
between averages to suppress artifacts from outer‐volume signals, imperfect flip angles, and imbalances in scanner electronics—a method known as phase cycling.6,7 Phase cycling
schemes are typically applied in blocks of 2, 4, 8, or 16 averages, which are repeated to attain the desired scan duration.
A further method to reduce artifacts originating from outside
the prescribed voxel is to ensure that the last slice‐selection
plane is perpendicular to regions of B0 inhomogeneity. For
example, having the final slice‐selection plane in the axial
direction has been shown to reduce SVS artifacts in frontal
brain regions by eliminating spurious signals caused by B0
inhomogeneity in the mouth and sinuses.7,8
All localization methods based on RF/gradient slice
selection, such as PRESS and STEAM, exhibit a localization inaccuracy known as the chemical shift displacement
(CSD) error. The CSD error causes a spatial displacement
of metabolite resonance localization, in which resonances
further from the center frequency of the RF pulse are displaced to a greater extent (Figure 2). Metabolites with
frequency‐separated J‐coupled multiplets, such as lactate,
may have reduced signal due to regions around the voxel
edge periphery not experiencing all 3 localization pulses
equally.9 For a given maximum RF amplitude (B1max),
the CSD error worsens with increasing field strength and
reduced RF pulse bandwidth. Therefore, CSD is worse
for PRESS than STEAM, as conventional 90° pulses have
greater bandwidth than conventional 180° pulses for a fixed
pulse duration and B1max. The CSD severity and reduction

will be described in the “Consensus opinion and recommendations” section.
In recent years, the development of the phased‐array head
coil10,11 has resulted in improved SNR for MRI and MRS,
and modern vendor‐supplied MRS protocols at 1.5 T and 3 T
are performed using the body (volume) coil for B1 transmission and a phased‐array head coil for B1 reception. Compared
with traditional transmit–receive (T/R) birdcage head coils,
the combination of phased‐arrayed receive and volume transmit offers improved SNR in cortical brain regions, due to the
close proximity of receive coils to cortical areas, and homogeneous B1 available from the volume transmit coil. In central brain regions, SNR gains are feasible using tighter‐fitting
receive coils. For well‐designed coils and optimized data
reconstruction,12-14 a higher number of array elements should
confer improved SNR in cortical regions, with a recent report
demonstrating a 40% improvement when using 32 elements
compared with 8.15 One potential disadvantage with using
body coils for transmission is reduced B1max when compared
with T/R designs; however, adequate B1max has been demonstrated at 3 T for low CSD sequences (see “Single‐voxel
spectroscopy acquisition consensus” section). Overall, the
use of phased‐array head coils with a high number of receive
elements is recommended for neuro SVS and MRS imaging
(MRSI) at 1.5 T and 3 T.

2.1.2 | Repetition time and TE
considerations
Proper determination of absolute metabolite concentrations
or ratios (e.g., total N‐acetylaspartate [tNAA]/total creatine
[tCr]) ideally requires long TRs and short TEs to minimize
signal loss from T1 saturation and T2 relaxation effects,
respectively. Short TEs (20‐30 ms) also offer improved
detection of metabolites with complex J‐coupled spectral
patterns (e.g., glutamine, glutamate, and myo‐inositol) due
to reduced dephasing from J‐coupling evolution. High‐quality short‐TE MRS allows the quantification of an extended
neurochemical profile, including neurotransmitters and antioxidants.16 However, a challenge associated with shorter
TEs is the enhancement of broad short‐T2 signals from
high‐molecular‐weight macromolecules (MMs) and lipids.17
Appropriate analysis methods are capable of separating
metabolite and lipid/MM signals, but poor B0 homogeneity
degrades this separation; longer TE acquisitions may be used
to suppress broad MM and lipid signals, and simultaneously
refocus weakly J‐coupled spins. For instance, a TE of 144
ms or 288 ms is used commonly to aid the discrimination
of lactate from lipids and singlets from overlapping multiplets. Although long TRs (> 2 seconds) reduce unwanted
signal loss per transient/average from T1 relaxation effects,
the metabolite SNR per unit time is also reduced; therefore, a
compromise is often required for clinical MRS.

WILSON et al.
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Comparison of vendor‐supplied MRS implementation of PRESS versus an advanced in‐house protocol using semi‐LASER79
and improved water suppression, shimming, and data processing on a 3T MRI system. Spectra (TE = 30 ms, TR = 5 seconds, 64 transients) were
acquired from the same voxel in the cerebellar vermis of a healthy volunteer. A, Water was suppressed by about 150 fold by the chemical shift–
selective sequence in the PRESS protocol and about 4500 fold by the variable pulse power and optimized relaxation delays scheme29 incorporated
into the semi‐LASER sequence. B, Chemical shift displacement (CSD) for resonances with a chemical shift difference of 3 ppm is 36%‐39% with
the PRESS sequence versus 6% with the semi‐LASER sequence in the 2 dimensions shown. C, Narrower linewidths (shown for the total creatine
[tCr] signal) are obtained with FASTMAP shimming18 in conjunction with single‐shot frequency and phase correction in the semi‐LASER protocol
versus product shimming and signal averaging in the PRESS protocol in the absence of motion during scanning. D, A small amount of motion
(few degrees in z such that the cerebellar volume of interest [VOI] was still acceptable at the extremes of motion) further degrades the linewidths
and generates unwanted coherences that are not removed with phase cycling in the PRESS protocol (highlighted by the circle). In contrast, spectral
quality is unchanged, with an acceptable water residual in the semi‐LASER protocol thanks to artifact‐free single shots and frequency and phase
correction of individual shots

FIGURE 2

532

|   

2.1.3

WILSON et al.

|

B0 inhomogeneity

|

Water suppression

In vivo susceptibility‐induced magnetic field distortions
arise from the presence of air/tissue and tissue/bone interfaces. In brain, field distortions are most apparent in regions
close to sinuses, such as the prefrontal cortex and temporal
lobes, and because susceptibility differences scale with the
static field strength, these distortions are stronger at higher
fields. A homogenous static magnetic field, B0, is essential
for MRS, as narrow linewidths provide the spectral resolution that is critical for observation of multiplet resonances,
accurate metabolite quantification, and efficient water suppression. In addition to gradient coils, MR systems incorporate shim coils to compensate for B0 inhomogeneity, and
adjustment of currents flowing through these coils is called
“shimming.”
Vendor‐provided shimming routines are currently based
on the acquisition of a 3D B0 field map (GRESHIM), B0 field
mapping along orthogonal projections (FASTMAP and its
variants),18-22 or along orthogonal planes of the localization
VOI. The B0 field variations calculated from signal‐phase
differences are used to compute the currents needed for each
of the available shim coils.23-25 The B0 field distortions over
typical SVS dimensions are generally compensated using a
first‐order shim (using the linear x, y, and z imaging gradient
coils) at 1.5 T, whereas the use of second‐order shim elements terms (z2, x2‐y2, x‐y, x‐z, and y‐z) is strongly recommended for SVS at 3 T.26

2.1.4

Detection of millimolar metabolite signals in the presence
of 3‐4 orders of magnitude higher water (~40 M) signals
is challenging due to the spectral baseline interference
originating from the tails of the large water resonance. In
addition, water “sideband” distortions, originating from
various sources including subject movement, as well as
mechanical vibration and instability of RF and gradient
electronics, produce spurious signals that further confound
metabolite signal estimates. Such interferences can be mitigated during acquisition by using a water‐suppression module before the MRS localization module. The most common
methods exploit the chemical shift difference between
water (4.65 ppm) and the strongest metabolite resonances
(4.2‐0.8 ppm). Common methods include repeated chemical shift–selective saturation pulses at the frequency of
water27; water suppression enhanced through T1 effects28;
and variable pulse power and optimized relaxation delays29
(Figure 2). In general, the effectiveness of water suppression is significantly affected by B0 homogeneity, as
methods require narrow‐bandwidth frequency‐selective
pulses to avoid inadvertent suppression of metabolite resonances closest to the water resonance.

2.1.5

|

Voxel dimensions and placement

|

Data analysis

In nonfocal diffuse brain disease or general physiological
studies, the SVS acquisition voxel is preferentially placed
far away from air/tissue interfaces, because of shimming
difficulties, and away from the scalp to prevent spurious
out‐of‐volume lipid signals. In a 5‐minute acquisition time,
an 8‐cm3 cuboid volume in parieto‐occipital gray matter or
parietal white matter provides high‐quality spectra at 1.5 T.
Smaller volumes down to 4 cm3 also yield spectra that allow
metabolite quantification beyond tNAA, tCr, and total choline (tCho) at 3 T within 5 minutes, provided that good B0
homogeneity can be achieved. In focal diseases or specific
anatomical areas of interest, voxels that best fit the targeted
anatomy or lesion are commonly used. Contamination by
lipid signals occurs for voxels located too close to the scalp,
and trial voxel placement in volunteers to assess slice‐profile
and CSD limitations experimentally is advised. In addition to
careful voxel positioning, outer‐volume suppression (OVS)
may be used to suppress signal from unwanted regions in
challenging areas. In general, volumes below 4 cm3 do not
have an adequate SNR if detailed metabolic profiles are
needed to answer clinical questions within a reasonable
5‐minute acquisition time, but may be acceptable for restricted
analysis such as the tCho/tNAA ratio in brain tumors. Voxel
volumes greater than 8 cm3 or prolonged scan times are
needed to detect small changes in low‐SNR metabolites such
as glutathione, and aid the discrimination between heavily
overlapped multiplets such as glutamate and glutamine.

2.1.6

Gross spectral features are amenable to expert visual interpretation (e.g., lipids that indicate a high‐grade tumor30);
however, automated analyses of metabolite signals provide
objective measures, such as relative metabolite concentrations or ratios, as biomarkers for clinical decision making and clinical trials.31 Magnetic resonance spectroscopy
analysis using basis sets of known metabolites, MM and
lipid signals parametrically fitted to the data with modeling
of baseline and peak line‐shape variations, have been particularly successful (Figure 1). Fitting may be performed in
the frequency domain, where baseline distortions may be
modeled as smoothly varying spline functions (LCModel32)
or decomposed using wavelets (VeSPA33). Time‐domain
analysis may also be used to reduce errors from baseline
signals by omitting initial data points from the fit, exploiting
the rapid temporal decay of baseline distortions (QUEST34,
TARQUIN35). Metabolite basis sets can be acquired experimentally or simulated from known parameters,36-38 and
either approach is effective.39,40 The addition of known
MM and lipid signals to the basis set results in improved
analysis, particularly for short‐TE data sets or tumor spectral
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analyses.41 B0 inhomogeneity and artifacts originating
from rapidly changing gradients, known as eddy currents,
broaden and distort the MRS line shape from its ideal form
(e.g., Lorentzian for singlet peaks). For accurate analyses,
these line‐shape variations should be reduced by correction based on the unsuppressed tissue water signal42 and/or
modeled during the fitting algorithm.32

2.1.7

|

Data quality

Quality control requires consideration of (1) SNR, (2)
metabolite and unsuppressed water resonance linewidths, (3)
residual water signal, (4) line shape, (5) Cramér‐Rao lower
bounds (CRLBs) of the data fit, (6) fit quality (relative size
of residuals versus noise SD), and (7) presence of artifacts
(spurious signals, baseline distortions, contamination from
subcutaneous lipids). The first 6 can be calculated automatically by spectral analysis software; however, the evaluation
of artifacts currently necessitates inspection by an experienced reader of MRS.43 Current automatic quality control
suffers from a lack of evidence‐based quality thresholds,
although general recommendations are available.1,44,45 An
accepted numerical quality estimate in relation to model
fitting of MRS data is the CRLB: a lower estimate of the
error of the concentration measurement as influenced by
SNR, linewidth, and mutual signal overlap. A relative CRLB
greater than 50% indicates that there is insufficient information to claim that the estimated value is significantly different
from zero; therefore, it is often considered to be unreliable.
However, it may also indicate that the estimated value is too
low to be reliably measured, which may be clinically significant.46 Influences from artifacts are not included in the
CRLB calculation, and these are illustrated and discussed in
Supporting Information Figures S1, S2, and Section B.

2.1.8

|

Absolute quantitation methodology

The obtained MR signal is proportional to the number of contributing 1H nuclei in the VOI, but the signal is not calibrated
and measurement of absolute metabolite concentration is
challenging due to unknown scaling factors such as receiver
coil sensitivity and loading. For metabolite ratios, these factors cancel, and for this reason metabolite ratios (e.g., tNAA/
tCr) are widely reported for clinical use, despite the ambiguity of attributing changes to the metabolite in the numerator or denominator. Additionally, small or inaccurate values
for the denominator produce large variance in a metabolite
ratio. Semiquantitative MRS can be obtained from the ratio
of each metabolite to the unsuppressed tissue water signal
from the same VOI and using an assumed MR visible tissue
water content.47 Full concentration quantitation requires correction of water and metabolite signals for relaxation factors,
assessment of any tissue partial volume effects (e.g., relative

|
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proportions of gray and white matter, CSF, or pathological
tissue in the VOI), and correction for disease‐induced water
concentration alterations.48 One challenge with concentration
measures is that accurate knowledge of water and metabolite
relaxation times are required, which may not be available for
pathological tissue (see Supporting Information Section C
for a discussion on relaxation‐time effects on quantitation).
In principle, using TEs shorter than 15 ms minimizes absolute quantitation errors of singlet peaks to less than 10% and
reduces the dependence on assumed T2 relaxation values;
however, technical challenges with accurate localization at
very short TE make this impractical with currently available
commercial MRS sequences.

2.2 | Magnetic resonance
spectroscopic imaging
Although SVS is appropriate for investigation of a focal
lesion, a specific anatomical region, or diffuse brain disease,
MRSI is preferred when the location of interest is uncertain
or multiple areas need to be evaluated simultaneously, such
as when investigating metabolite distributions across heterogeneous lesions due to a tumor. In its most commonly used
implementation at 3 T, a 16 × 16 grid of spectra with nominal voxel resolution of 1.5 cm3 may be acquired in approximately 5 minutes at a TR of 1500 ms, with 1 average per
phase‐encoding step and elliptical k‐space sampling. Despite
the advantage of spatial metabolite information offered by
2D and 3D MRSI, robust acquisitions of good‐quality data
present significant challenges. Practical issues include achieving adequate B0 homogeneity over a large volume for good
spectral resolution and reliable water suppression, good scalp
lipid suppression, and automated and accurate analysis of large
multivoxel data sets and their presentation for intuitive interpretation. In the following sections, we briefly introduce the
technical issues surrounding MRSI acquisition and analysis.

2.2.1

|

Localization and phase encoding

Contrary to a small voxel that is selected in SVS, in MRSI
a larger volume is selected to acquire signals from multiple
voxels across a 2D or 3D grid. This volume can be a slice
through the brain, acquired using single slice‐selective excitation and refocusing pulses combined with OVS slices to
suppress scalp lipid. A single 2D slice or 3D cubic volume
can be selected with orthogonal slice‐localization methods
such as PRESS or STEAM as described for SVS. Within
the selected slice or volume, 2D or 3D phase encoding is
performed to localize spectral signals to a specific grid location. Outer‐volume suppression is essential in slice‐localized
acquisitions to suppress subcutaneous lipid signals, and may
be used in combination with PRESS or STEAM localization
to reduce spurious outer‐volume and scalp lipid signals. The
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OVS slices are also used to create a target VOI that better
conforms to the brain shape and a relevant tissue region, as
well as aid in the optimization of shimming and water suppression over a more restricted region (Figure 3).
Although the CSD, which is expressed as the displacement/
ppm as a percentage of the localization width (%CSD), remains
constant for a particular sequence, absolute CSD increases proportionally with the prelocalization dimensions. Therefore,
increased in‐plane CSD is a significant problem for MRSI, in
which localization volumes are much larger compared with
SVS. Typical 2D MRSI PRESS implementations at 3 T have
an in‐plane %CSD of over 10%/ppm, resulting in a relative

WILSON et al.

displacement of 1.2 cm between tCho and tNAA localization
volumes for a 10 × 10 × 1 cm3 axial PRESS volume, in both
the left–right and anterior–posterior directions (Figure 4).
The phase‐encoding localization method is based on
the incremental adjustment of the strength of an applied
magnetic gradient field and may be applied to MRS acquisitions to create a “spectroscopic” image.49,50 Unlike slice localization described previously, localization by phase encoding
does not exhibit CSD effects or geometrical distortions due
to B0 inhomogeneity, and allows relative metabolite signal
frequencies to be preserved independent of spatial position.
Although data matrix sizes are small in MRSI compared with

F I G U R E 3 Three‐dimensional MRS imaging [MRSI] (bottom left: TE = 144 ms, TR = 1.25 seconds; bottom right: TE = 35 ms, TR = 1.3
seconds) acquired at 3 T from a patient with glioblastoma. Both scans had a nominal voxel resolution of 1 cm3, and 4‐Hz spectral apodization was
applied. The PRESS excitation volume (yellow rectangle) and 8 very selective saturation (VSS) outer suppression bands (shaded purple) are shown
in the top panel. Both the PRESS volume and VSS outer suppression bands were automatically prescribed using in‐house software.107 Good‐quality
spectra from the red gridded region (top) of slices close to the center of the PRESS box are highlighted for both long and short TEs (bottom)
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F I G U R E 4 Two‐dimensional PRESS CSI acquired at 3 T in a healthy volunteer using TR = 2000 ms, TE = 32 ms, and elliptical sampling
from a 20 × 20 k‐space grid with nominal voxel size of 10 × 10 × 10 mm3 and 13‐minute acquisition time (including a reduced spatial‐resolution
water reference for zero‐order phasing). Spectral data are shown over the range of 0.5 ppm to 4 ppm for the central 10 × 10 voxels, and the
PRESS localization volume was prescribed as the outer edge of the grid with the transmitter frequency set to the expected frequency of the total
N‐acetylaspartate (tNAA) resonance at 2.01 ppm. Spectra were analyzed with LCModel, and the metabolite maps are shown in a false color scale
normalized to a maximum of 1.0. The PRESS volume edge is defined at the zero excitation level (i.e., the lower tNAA signal in all outer voxels).
There are much greater reductions in tCho and tCr in the top rows and right columns due to CSD relative to tNAA, which was the metabolite set
on‐resonance for the PRESS localization. Thus, the absolute signal intensity is modulated by the nonuniformity of the PRESS excitation and further
convolved with the CSD effect when metabolite ratios are used

MRI, acquisition times become substantial as spatial resolution increases or if 3D data are required (e.g., > 51 minutes for 3D MRSI when acquiring a full 16 × 16 × 8 matrix
with TR of 1500 ms). To reduce acquisition times, higher
frequency spatial components are sacrificed by limiting the
k‐space acquisition to a spherical or elliptical region, instead
of a rectangular one, which reduces measurement time by
25% for 2D and 50% for 3D MRSI.
The MRSI acquisition planning and results are typically
displayed as a grid of voxels, in which the nominal voxel
dimensions in the phase‐encoded directions are determined
by the FOV divided by the number of phase‐encoding steps.
Unlike SVS, in which it can be reasonably assumed that most/
almost all signal originates from the prescribed voxel location,
MRSI “voxels” may have a significant amount of signal contribution from outside the displayed grid boundaries or nominal voxel volumes. The point‐spread function (PSF) describes
precisely how the signal from the surrounding area contributes
to a location on the MRSI grid. For phase‐encoded MRSI, the
PSF is a complex sinc function; therefore, the signal within
a voxel includes positive and negative contributions that
decrease with distance from the voxel center (Figure 5A,C).
Scalp lipids are particularly prone to producing signals that are
localized within the MRSI grid, distant from their true spatial origin (known as signal “bleed”) due to the MRSI PSF.
These artifacts can often cause significant spectral distortion

and confound the true estimation of metabolite and lipid levels
originating from brain tissue.

2.2.2 | Acquisition‐based suppression of
scalp lipid
Scalp lipid suppression may also be achieved with OVS,
frequency‐selective saturation, and inversion recovery (IR)
methods, either in isolation or in combination with PRESS
or STEAM localization. Outer‐volume suppression is typically applied using 8 perpendicular planes to the MRSI excitation, arranged in an octagonal pattern around the scalp.51
Outer‐volume suppression maintains target region signals,
but is cumbersome to plan and has limited lipid suppression
efficiency. The IR approach with a non‐frequency‐selective
adiabatic inversion pulse is relatively insensitive to B1 inhomogeneity and eliminates the need for careful OVS prescription.52 A drawback of IR lipid suppression, however, is that
T1 relaxation also occurs for metabolites in the IR period,
resulting in unwanted metabolite T1 weighting and signal
loss (approximately 25% at 3 T), which is greater the shorter
the metabolite T1 is. For many neurological disorders, intracerebral lipids are not of interest; hence, global lipid suppression using IR is inconsequential. However, lipid signals in
the target volume are important diagnostically for tumors,
stroke, and lipid metabolism disorders.
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F I G U R E 5 The one‐dimensional point spread function (PSF) for phase‐encoded MRSI with 16 points (A) and with reduced spatial signal
spread and resolution when applying a Hamming k‐space filter (B). The PSF of the more commonly used 16 × 16 circularly sampled 2D phase‐
encoding scheme for MRSI is illustrated in (C) and the corresponding Hamming‐filtered PSF is shown in (D). A nominal resolution of 1‐cm and
16‐cm FOV was used for all plots. Due to the PSF and its filtering, the effective voxel size is considerably larger than the nominal voxel size

2.2.3

|

B0 inhomogeneity

Adequate shimming is significantly more difficult for MRSI
compared with SVS. The B0 inhomogeneity must be corrected over a larger tissue volume, and B0 inhomogeneity
in regions close to the scalp or sinuses may exacerbate artifacts due to PSF effects. Whole‐brain 3D MRSI with first
and second‐order shimming may have up to 35% of voxels
with insufficient data quality for analysis at 3 T.53 B0 heterogeneity is so large across the whole brain that the required
shim strength for optimal homogeneity increases by an order
of magnitude going from a slice above the ventricles to the
temporal lobe.54 Therefore, the need for adequate shimming
hardware with second‐order shim coils and associated high‐
power amplifiers, combined with reliable software shimming
algorithms, is particularly important for MRSI.

2.2.4

|

Parallel imaging

For MRSI over large brain volumes, phased‐array head coils
provide improved sensitivity in cortical brain regions and
enable the use of parallel reconstruction methods, such as
SENSE, to improve spatial resolution or reduce scan times.
Potential artifacts from parallel imaging methods include

incorrectly localized signals, due to the imperfect reconstruction, which may not be visually obvious for metabolites in
low‐spatial‐resolution MRSI data. However, incorrectly
localized scalp lipids signals are generally more notable,55-57
which may be shifted in frequency due to B0 inhomogeneity and aliased to obscure metabolite peaks. Additional
challenges in accurate reconstruction are due to metabolite
signals having a considerably lower concentration, and therefore SNR, compared with water. Self‐calibration parallel
imaging methods, such as GRAPPA, have also been applied
to MRSI acquisition.58 The full impact of parallel imaging
methods on MRSI metabolite quantification levels is still
under investigation.53,59,60

2.2.5

|

Postprocessing

With multichannel coil acquisitions, corrections for coil‐
dependent signal strength and phase characteristics for each
spectrum must be made to combine the data optimally.12-14,61
An MRSI scan of the unsuppressed water obtained at low
spatial resolution can aid zero‐order phasing, frequency
offset, and line‐shape corrections of the metabolite spectra
without a major time penalty. With phased‐array coils and
SENSE, a water‐reference signal for metabolite quantitation
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may be acquired at the same spatial resolution as the metabolite scan, but with a significantly reduced scan duration as an
alternative to a low‐resolution acquisition.62
Following recombination of data from the individual coil
elements, zero‐filling of the k‐space data is often used to
reduce the apparent voxel size and produce smoother‐looking metabolite maps. However, this step only amounts to
interpolation and does not reduce the effects of the PSF or
increase spatial resolution. Spatial filtering is often applied
to reduce Gibbs ringing artifacts from scalp lipid and from
truncation artifacts associated with reduced k‐space acquisitions.63 This also causes widening of the central lobe of
the PSF, resulting in improved spectral SNR, but reduced
spatial resolution. Figure 5 illustrates the influence of the
commonly used Hamming filter on the PSF for typical MRSI
acquisition parameters. Subsequent to processing the MRSI
data in k‐space, 2D or 3D spatial Fourier transformation is
applied to generate a series of FIDs for each voxel. These
may be analyzed in the time or frequency domain with the
same methods used for SVS, or simply Fourier transformed
in the chemical shift dimension to create an array of spectra
for a visual assessment.

2.2.6

|

Data analysis and metabolite maps

Two‐dimensional and 3D MRSI produce large amounts of
data; therefore, robust, automated data processing to generate metabolite maps is needed for ease of clinical interpretation. Acquisitions at 3 T with phased‐array head coils have
greater spatial variation in receive sensitivity than studies
at 1.5 T with quadrature or birdcage head coil designs, and
at 3 T dielectric effects can compromise RF transmission
homogeneity. Hence, using a semiquantitative approach with
reference to contralateral brain or a coil reference sample
are problematic. The MRSI metabolite concentrations can
be calculated if an additional water reference is acquired48;
however, the associated time penalty may be significant
(when using conventional methods), as all phase‐encoding
steps need to be repeated. Metabolite ratio maps can be more
robust than maps of “absolute” levels (albeit semiquantitative
if relaxation effects are ignored), as they are less sensitive
to tissue partial‐volume effects with CSF. However, partial‐
volume effects between tissue types such as gray and white
matter,64,65 or normal and diseased tissues,66 are important to
consider when interpreting the data.

2.2.7

|

Cautions and quality control

Automatically generated metabolite maps can be unreliable
due to the effects of poor water suppression, lipid contamination and B0 inhomogeneity, and they are degraded by subject
motion and inaccuracies of spectral fitting. Therefore, quality assessment of individual spectra and their fit is a required
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step for proper interpretation. However, visual quality assessment is often impractical with MRSI, resulting in a need for
automated methods to exclude poor‐quality data. The relative
CRLB derived from fitting each spectrum to a model function is misleading as a numeric estimate of data quality if
there is a real absence of specific metabolites; however, good
CRLB values may also arise from fitting bad‐quality spectra if the noise is underestimated, artifacts are present, or the
fitting method has converged to an incorrect solution (local
minimum). Alternative quality measures include CRLB values from a fit to a co‐located water signal, using confidence
limits67 and linewidths from spectral fitting of metabolites or
water, detection of outlying values in the spectrum,68 and use
of pattern recognition to classify poor‐quality spectra.44,69,70
A quality map enables easy interpretation at the time of the
clinical read, such as implemented in the MIDAS software71
(Figure 6). Nevertheless, a visual assessment of spectra in
key diagnostic locations is still advisable, and a zoomed‐in
grid of the raw spectra overlaid on the MRI of the abnormal
region adds confidence to any interpretation of metabolite
maps.
In addition to poor‐quality data, visual interpretation
of metabolite maps can present difficulties, particularly at
the low spatial resolution of MRSI as compared with MRI,
for which partial‐volume effects can be significant. Highly
interpolated MRSI data can give a misleading impression of
spatial detail, and PSF effects reduce the actual spatial resolution and may create artifactual “hot” or “cold” spots. B0
inhomogeneity can cause localized signal loss, which may be
obvious in temporal–frontal brain regions due to proximity
to sinuses, but can also occur in areas of blood breakdown
products or calcification, and close to surgical entry points
(e.g., craniotomy staples). Finally, maps of metabolite ratios
can include exceptionally high values because of a division
by a small metabolite value, and visual inspection is required
to interpret these regions correctly.

3 | CONSENSUS OPINION AN D
RECOM M ENDATIONS
The following discussion is based on the results of an MRS
technical consensus survey completed by 35 experts in clinical MRS (Supporting Information Section A) and subsequent discussions among all authors. The survey aimed to
determine what specifically could be recommended as best
practice using the current standard implementations of 1H
MRS, and to define current limitations of scanner hardware and software. The survey also indicated the practical
solutions that have been developed within the research environment. Key areas inhibiting the more widespread clinical
use of MRS are limitations in shimming algorithms, the practicalities of voxel planning and the time penalties associated
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Illustration of spectral quality maps generated by the MIDAS software package.71 A, T1‐weighted MRI corresponding to the
selected MRSI slices. B, Raw tNAA signal intensity map. C, Spectral quality map, showing regions that passed the quality criteria for metabolite
linewidth of 0.1 ppm or less (white). Regions that failed metabolite linewidth‐quality criteria, but passed water‐reference linewidth criteria, are
shown in light gray. Regions that failed both linewidth criteria are shown in dark gray. C, The tNAA map with the identified poor‐quality voxels set
to zero. Note the signal dropout in much of the anterior cingulate cortex, related to insufficient shimming close to air–tissue interfaces (e.g., sinuses,
ear canals). Data were obtained using volumetric (3D echo planar spectroscopic imaging [EPSI]) proton (1H) MRSI with lipid inversion nulling at
3 T, TE/TR/TI = 17.6/1550/198 ms, 50 × 50 × 18 k‐space points over 280 × 280 × 180 mm3, and total acquisition duration of 16 minutes

FIGURE 6

with these processes, as well as reliable data processing and
display. All of these issues are significantly exacerbated for
MRSI. We indicate solutions to these issues and provide
guidance for recommended acquisition and data‐processing
protocols within the context of current scanner capabilities.

3.1

|

Single‐voxel spectroscopy acquisition

Point‐resolved spectroscopy localization is the current standard for SVS and is commercially available from all scanner
manufacturers. We recommend a maximum CSD level of 4%/
ppm, in which the percentage relates to the spatial displacement as a proportion of the slice‐selection width. This maximum recommended level of CSD is achieved at 1.5 T, but
exceeded in some implementations at 3 T due to insufficient
bandwidth of conventional RF pulses resulting from a limited
maximum transmit field B1max. Increased CSD makes planning and interpretation of SVS more challenging due to different metabolite signals being localized to different volumes.
Therefore, methods to reduce CSD, while maintaining good
SNR, short TEs and accurate localization, should be used to
achieve the full advantages of clinical MRS at 3 T. One of the
first approaches to reduce CSD was the use of very selective

saturation (VSS) pulses that have high bandwidth and can suppress an outer‐volume signal with minimal CSD. Conventional
PRESS is used to excite a larger (approximately 20%) region
than required, and VSS pulses redefine a smaller region with
minimal CSD,72,73 a method known as OVERPRESS.
Adiabatic pulses have a substantially greater bandwidth
(for a given B1max) than the conventional refocusing pulses
used in the PRESS sequence and were first applied to 3D,
single shot localized MRS in the SADLOVE sequence,74,75
and later employed in the closely related LASER sequence.76
More recently, the semi‐LASER77-79 sequence has been
developed, replacing the adiabatic excitation pulse of LASER
with 1 conventional slice‐selective excitation pulse to reduce
the minimum achievable TE. Higher‐order hyperbolic secant
adiabatic full passage or gradient‐modulated offset‐independent adiabaticity pulses may be used for refocusing in semi‐
LASER, with the latter using wideband, uniform rate and
smooth truncation RF and gradient waveform modulation.80,81
The advantage of gradient‐modulated offset‐independent adiabaticity pulses compared with hyperbolic secant adiabatic
full passage is a reduced maximum B1 strength required for a
given pulse bandwidth, enabling semi‐LASER to be used at
short TE (~30 ms) on 3T systems with a maximum available
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B1 strength of 13‐15 µT.82 In addition, gradient‐modulated
offset‐independent adiabaticity semi‐LASER has a reduced
RF power deposition compared with hyperbolic secant adiabatic full‐passage pulses of the same bandwidth, enabling
the sequence to be used with a shorter TR and at higher field
strengths within specific absorption rate limits. Although
adiabatic pulse pairs offer improved resilience to B1 inhomogeneity, their primary advantage for SVS at 3 T is increased
bandwidth and slice‐selection profiles, thereby reducing CSD
to acceptable levels. A further advantage of semi‐LASER,
compared with PRESS for the same TE, is longer apparent
T2 relaxation times and partially suppressed J‐coupling evolution, due to the Carr‐Purcell‐Meiboom‐Gill‐like refocusing
pulse train (and therefore enhanced detection of complex multiplets such as glutamate.)79,83
Overall, we recommend the use of semi‐LASER due to
its recent validation studies84-89 and increasing availability on clinical systems, as both research work‐in‐progress
sequences and commercial product (Figure 2). Furthermore,
in our consensus survey, semi‐LASER was ranked as the
most likely localization technique to improve clinical MRS.
We also recommend the use of PRESS with VSS pulses if
this is the only option available, but note this option lacks the
partially suppressed J‐coupling evolution and longer apparent T2 relaxation when compared with semi‐LASER, and can
inadvertently excite or refocus large signals (e.g., scalp lipids) that are difficult to suppress fully.
In general, we recommend the shortest achievable TE for
SVS at any field strength, assuming that CSD remains within the
TABLE 1
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acceptable range of 4%/ppm and appropriate analysis methods
are used to model the increased amplitude of macromolecular
and lipid signals. The advantages of using the shortest possible
TE include (1) improved SNR due to reduced T2 relaxation,
(2) more accurate concentration estimation due to a reduced
dependence on assumed metabolite T2 values, and (3) improved
SNR for J‐coupled metabolite signals due to reduced dephasing.
Other TEs may be appropriate for improved detection of specific metabolites, such as lactate/alanine at a TE of 144 ms or
TE of 97 ms for 2‐hydroxyglutarate with PRESS.90 Longer TEs
may also be preferred to improve water and lipid suppression,
due to their shorter T2 compared with metabolites, or if optimal
long TE biomarkers are targeted, such as tCho/tCr in glial tumor
grading.91 A SVS TR of 1.5 seconds at 1.5 T and 2.0 seconds
at 3 T is recommended to provide the maximum SNR per unit
time, on average, for the main metabolite signals from tCho, tCr,
tNAA, and lactate. Further justification and discussion on the
compromise among TR, SNR, and T1 saturation may be found in
Supporting Information Figures S3, S4, and Section C).
The recommended number of averages for typical voxel
dimensions of 15 × 15 × 15 mm3 and 20 × 20 × 20 mm3
for 1.5 T and 3 T are given in Table 1. A reduction in voxel
dimensions results in a loss of SNR; therefore, additional
averages are required to attain suitable quality data. Note that
SNR scales with the square root of the number of averages.
Accordingly, an unacceptably long time is required for the
15‐mm‐sided cubic voxels to attain the same SNR as with the
20‐mm‐sided cubic voxels; therefore, the recommended averages represent a compromise that results in an SNR reduction

SVS acquisition consensus summary

Aspect

Consensus

Localization method

CSD of less than 4% per ppm.
3 T: Semi‐LASER with OVS (preferred) or OVERPRESS with VSS.
1.5 T: Semi‐LASER with OVS (preferred) or PRESS.

TE and TR

TE as short as possible (typically 30 ms). Longer TEs may be preferred for lactate (144 ms or 288 ms) at TEs
optimized for specific metabolites, such as 2HG detection, and for enhanced lipid suppression.
TR = 1.5 seconds at 1.5 T, 2.0 seconds at 3 T.

Number of averages,
voxel dimensions,
and sampling
parameters

128 averages collected from a 15 × 15 × 15 mm3 VOI at 3 T.
64 averages from a 20 × 20 × 20 mm3 VOI at 3 T.
256 averages collected from a 15 × 15 × 15 mm3 VOI at 1.5 T.
128 averages from a 20 × 20 × 20 mm3 VOI at 1.5 T.
Spectral sampling of 1024 complex data points from 2000‐Hz spectral width at 1.5 T or 3 T.

Water‐reference
acquisition

Recommended in all cases. Collect with the same sequence parameters as the water‐suppressed scan, but without water
suppression and the transmitter frequency set to the water resonance. A single average should be collected with a
pre‐acquisition delay time of at least 9 seconds to prevent T1 weighting

B0 shimming
hardware

Second‐order shim coils with adequately powered amplifiers are recommended at 3 T.

B0 shimming
algorithm

Methods incorporating shim‐strength limits and instability countermeasures are preferred over unconstrained
approaches.

Abbreviations: 2HG, 2‐hydroxyglutarate; OVS, outer‐volume suppression.
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of 40% for the smaller voxel size. However, because shimming is generally improved for smaller voxel sizes, some signal loss is mitigated by narrower linewidths.
In addition to water‐suppressed data, which are required
for metabolite level/concentration estimation, a matched
unsuppressed water‐reference acquisition (acquired with
the transmit frequency set to the water resonance) is recommended as part of all SVS clinical protocols. Because the
water resonance has high SNR compared with metabolites,
we recommend acquiring a single average for the water‐
suppressed data. When possible, a minimum period of 9
seconds without RF excitation should be ensured before
acquisition, to essentially eliminate T1 weighting for water
in normal and pathological tissue. A 9‐second delay also
ensures that the T1 saturation signal loss is less than 10%
in cystic regions or CSF. Dummy scans should be used to
achieve a steady state in cases in which the recommended
relaxation period cannot be guaranteed. The water signal
may be used to correct for eddy current line‐shape distortions42; estimate B0 field homogeneity and frequency
offset; evaluate water‐suppression quality; and provide
metabolite concentration scaling information for use with
short TE acquisitions.47

3.2 | Magnetic resonance spectroscopy
imaging acquisition
The MRSI acquisitions excite a much larger volume of tissue
compared with SVS; therefore, a more stringent maximum
CSD of 2% per ppm (across the selected volume) is recommended. Any CSD levels greater than 2% per ppm result in a
significant loss of metabolite information around the edges of
the MRSI excitation region, making it challenging to obtain
the required spatial coverage in the cortex, such as avoiding
unwanted excitation of scalp lipids. It is recommended that
edge voxels be excluded from the from data analysis. We recommend the use of semi‐LASER over PRESS for 3T MRSI
prelocalization, due to its reduced CSD level and additional
reasons stated in the SVS acquisition section. Where available, the use of high‐bandwidth spatially selective saturation
bands92,93 are also recommended to improve conformance
between the excitation volume and the region of interest by
suppressing scalp lipid regions that are unavoidably excited
by the prelocalization scheme. Standard OVS is also recommended for suppressing signals from brain areas with significant B0 inhomogeneity (e.g., frontal sinuses), to reduce
PSF‐related distortion spread. A narrower PSF, resulting
from acquisition with higher in‐plane resolution, is also recognized as an effective strategy for reducing scalp lipid contamination—provided that the extra scan time and reduced
SNR can be tolerated.
For 2D phase‐encoded MRSI, we recommend the use of
elliptical sampling in k‐space and TRs of 1.5 seconds at 1.5
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T and 2.0 seconds at 3 T (Supporting Information Section C).
The phase‐encoding FOV should fully encompass the prelocalization volume to avoid aliasing, and the use of a 16 ×
16 imaging matrix with 10‐mm in‐plane resolution and slice
thickness of 15 mm is recommended as a default protocol.
Note that the recommended spatial coverage and resolution
parameters are intended as a starting point only, and may
need to be adjusted to match the disease location, extent, and
clinical question. For instance, in the case of inadequate prelocalization, the phase‐encoding FOV should be increased to
contain regions of spurious signals to avoid aliasing. As with
SVS, short TEs (approximately 30 ms) are recommended for
MRSI, due to the greater level of metabolite information,
higher SNR, and reduced T2 bias in concentration estimates.
However, in areas of greater B0 inhomogeneity, where water
and lipid suppression are less effective, longer TEs may be
necessary to reduce water and lipid signals relative to metabolites. An unsuppressed MRSI water scan should be acquired
to aid line‐shape correction, phasing, chemical‐shift referencing, and quantitation. Because an additional MRSI water
acquisition doubles the effective scan time for MRSI at the
same spatial resolution (unlike SVS), a reduced resolution
acquisition or parallel imaging62 approach may be used to
mitigate the associated time penalty for acquiring the unsuppressed water MRSI.
Although 2D phase‐encoded MRSI with prelocalization
is currently the most commonly used MRSI technique in the
clinical environment, there is strong interest in the development of robust whole‐brain MRSI within a clinically feasible
acquisition time. In addition to the obvious advantages for
studying diseases that are known to affect multiple brain areas,
such as neurodegeneration,94 the ability to plan an MRSI
acquisition as easily as standard MRI (i.e., without having to
preselect a region of interest) will improve data consistency
and acceptance in clinical centers. The use of prelocalization
also significantly restricts spatial coverage, making it very
difficult to study cortical regions near to the surface of the
brain. Using conventional phase encoding, 3D MRSI is only
practical for limited brain regions when there is the option of
highly efficient OVS. For instance, the use of VSS pulses73
or a 3D 8 × 8 × 8 MRSI matrix of 15‐mm isotropic voxels
provides good quality data in 12.8 minutes for a TR of 1500
ms and a full k‐space acquisition. For whole‐brain examination, 3D MRSI is prohibitively time‐consuming; therefore, a
number of fast acquisition methods have been developed by
the research community.
The most commonly used whole‐brain MRSI acquisition is
the echo planar spectroscopic imaging (EPSI) technique,95-97
in which an oscillating readout gradient generates an echo
train, encoding a full plane of k‐space for each excitation.
When applied to the proton nucleus, PEPSI (proton PEPSI)
is also used to describe the same sequence98; however, we
generally recommend the use of the more generic term EPSI.
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The chemical shift and 1 spatial dimension are simultaneously
encoded during the gradient‐echo readout, and phase encoding is used for the 2 remaining spatial dimensions. Recent
implementations of EPSI use either whole‐slice/slab acquisition with OVS99,100 or whole‐brain acquisition with lipid
inversion nulling and postacquisition k‐space extrapolation101
to significantly reduce scalp lipid contamination. In addition,
an interleaved water acquisition is used to improve reconstruction in the presence of B0 inhomogeneity and drift, and to provide a reference signal for metabolite concentration scaling.102
Unlike many other MRSI approaches, the whole‐brain 3D
EPSI sequence has been implemented and tested on instruments from 3 manufacturers with encouraging consistency
across sites.103 The main advantages of this sequence are
greater coverage of the cerebrum and simpler planning. This
sequence has been reported to sample, on average, 70% of the
brain volume,104 although with instrumentation‐dependent
differences. Recent 3T studies using whole‐brain 3D EPSI
have been able to achieve an acquisition time of 18 minutes
with a TE of 20 ms, which may be acceptable for clinical trials and some specialized clinical assessments.105 Shorter scan
times are feasible using partial‐brain 3D EPSI.100,106
An alternative approach for whole‐brain MRSI is to combine medium‐resolution EPSI encoding (10‐mm isotropic)
with OVERPRESS localization and automatically prescribed
VSS bands.107 This sequence is relatively fast to acquire (13
minutes) and does not require lipid inversion nulling, which
also suppresses potentially useful lipid signals originating
from pathology. In addition, the automated prescription of
this sequence is much more practical for clinical use when
compared with manually prescribing PRESS volumes in
combination with saturation pulses and shim volumes. This
approach has been tested on a clinical cohort of brain tumor
patients with encouraging results.107
Considerable progress toward robust whole‐brain MRSI
has been made in recent years, and a wide range of techniques
has been demonstrated to provide high acceleration.106,108
At the time of writing, we were unable to recommend one
whole‐brain MRSI approach over another, and identified a
need for comparative studies to assess the relative performance of the various approaches.

3.3 | Single‐voxel spectroscopy and MRSI
preprocessing and analysis
Fully automated analysis methods, which perform phase correction, chemical shift calibration and quantitative analysis of
metabolite signals, have been available for 25 years32 and are
strongly recommended for MRS analysis. A choice of commercially licensed (LCModel32), free (jMRUI109), and open‐source
(e.g., TARQUIN,35 MIDAS,71 SIVIC,110 VeSPA [http://scion.
duhs.duke.edu/vespa/]) software packages have been developed, predominantly by the research community, and are
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available for offline data visualization and analysis. Analysis
methods available on the scanner software are typically inferior
to those used in dedicated software packages, and an improvement in this area would greatly benefit clinical MRS. There is
currently no clear consensus on the best analysis algorithm for
use in all cases; however, a common feature of the most widely
used methods is the use of a quantum mechanically simulated
set of metabolite spectra (basis set) into the fitting routine.
Modeled lipid signals and modeled or measured macromolecular signals can be included in the basis set when appropriate
(e.g., short TE protocols or investigations of pathologies with
hypoxic/necrotic processes such as stroke and tumors).
The jMRUI, TARQUIN, and VeSPA packages have metabolite basis simulation integrated into the analysis software. In
the case of jMRUI, metabolite simulation is performed using
the NMRSCOPE‐B111 method and VeSPA makes use of the
GAMMA library.112 The FID‐A package also provides tools
to simulate metabolite basis sets, in addition to preprocessing
steps and data export options for fitting to be performed with
other software.113 We recommend the use of analysis methods based on fitting with simulated metabolite basis sets over
single‐peak modeling or spectral integration, as simulated
basis sets conveniently incorporate a greater level of prior
knowledge38,41 into the fitting process, which can easily be
adapted to match the acquisition protocol.
Quality assessment must be an integral part of MRS analyses, as distorted or poorly fit data leads directly to erroneous
results. Metabolite SNR and linewidth estimates are recommended as objective measures of data quality. A number
of spectral SNR definitions have been described for MRS.
Here, we recommend that the signal measure be defined as
the height of the largest metabolite data point in the real part
of the spectrum minus the fitted baseline at that point; and the
noise measure as 2 times the SD of the spectral data points in
a region free from metabolite signals, residual water, or other
spectral distortions. Although other measures of spectral
SNR are acceptable, reported values should be accompanied
by a definition to avoid ambiguity; for example, the current
version of the LCModel32 analysis package defines the noise
as 2 times the SD of the fit residual. Linewidth estimates
(FWHM) are also usually measured, in units of hertz or parts
per million, from the real part of the phased spectrum and are
typically derived from the most prominent singlet metabolite
or unsuppressed water resonance. Although universal guidelines for acceptable MRS data quality are challenging, due to
the heterogeneous metabolite profiles of diseases and wide
range of acquisition protocols, spectra with FWHM greater
than 0.1 ppm should be regarded as being of poor quality. A
minimum metabolite SNR of 3 is recommended to confirm
the presence of a particular singlet; however, greater metabolite SNR values are required for accurate quantification or
detection of coupled multiplets. Sample spectra with different SNR and FWHM values are shown in Figure 7.
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F I G U R E 7 Simulated “normal brain” spectra for a typical PRESS acquisition at 3 T (TE = 30 ms, 1024 data points, and 2000‐Hz sampling
frequency). The SNR and FWHM values are given for the largest singlet resonance (tNAA)

Although SNR and linewidth criteria are useful for basic
quality assessment, a visual inspection of fitting results remains
important, as analysis errors and data artifacts may produce
unrealistic values. Furthermore, these values do not reliably
detect a number of quality issues such as unstable or unrealistic
baseline estimates during fitting or out‐of‐volume lipid contamination. To aid visual assessment, we recommend that the analysis output include plots of the phased spectra with the fit and
estimated baseline and residual for retrospective visual assessment of the data (example given in Figure 1 with the optional
addition of individual basis signals). For SVS, a quick visual
assessment of the data and fit quality can easily be performed
by someone with a basic understanding of MRS and common
artifacts,43 and this approach is suitable for the clinical environment. However, for MRSI, where hundreds of spectra are
typically acquired in a single scan, visual assessment is often
impractical and there is great interest in developing automated
quality assessment. One of the first approaches, based on the
classification of independent spectral components, was found
to provide 87% agreement with expert spectroscopic evaluations.70 More recently, methods based on random forest classification of spectral data69 and features extracted from the time
and frequency domain114 have also been shown to provide high
agreement with expert assessment. Although these techniques
are an important step toward fully automated MRS quality control, their applicability across different scanners, experimental
protocols, and clinical scenarios requires further investigation.

Before SVS fitting, eddy‐current correction using the
unsuppressed water reference is recommended to reduce
metabolite signal line‐shape distortions.42 There is also an
increasing trend toward retrospective frequency and phase
correction of each average and elimination of motion‐
corrupted FIDs prior to signal averaging.115-117 Although
these methods have been successfully applied to scans with
high metabolite signal (e.g., normal appearing brain), their
suitability for low‐SNR clinical spectra (e.g., brain tumors)
has not been fully investigated and therefore should be
used with caution. We also note the promising approach
of using “metabolite‐cycled” MRS for retrospective correction using the water signal, allowing low‐SNR spectra
to be accurately corrected, while maintaining metabolite
spectral quality.118
The analysis pipeline for MRSI includes preprocessing
steps to aid interpretation. K‐space filtering with a suitable window function, such as Hamming, is recommended
for reducing distortions from Gibbs ringing of high‐intensity signals such as scalp lipids. Fourier interpolation, by
k‐space zero filling, to twice the acquired dimensions is
also recommended to aid display and interpretation of
metabolite maps. Optimized reconstruction methods, such
as the Papoulis‐Gerchberg algorithm, are also recommended to reduce lipid artifacts.101 More recently, a variety
of novel reconstruction methods were shown to suppress
MRSI lipid signals119-122 with promising initial results, but
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validation on clinical data is required before recommending them for general use.

3.4 | B0 inhomogeneity and water
suppression
The current generation of commercially available shimming
and water‐suppression algorithms does not provide the reliability and robustness needed for performing MRS/MRSI at all
locations in the brain. In addition to being quite time‐consuming, these drawbacks are important impediments to the wider
clinical use of MRS. Therefore, we encourage the research community and MR vendors to optimize the performance of shimming, water suppression, and power‐calibration steps in both
favorable and challenging brain regions.
Both projection (FASTMAP and variants) and volumetric
mapping acquisition methods are widely available, and can be
effective for B0 shimming, with projection methods generally
taking less time. A recent study demonstrated that FASTMAP
linewidths were 40% better than a vendor implementation of
volumetric mapping for an 8‐mL SVS VOI in the posterior
cingulate cortex.85 We note that the vendor implementation
of volumetric mapping has since been updated and improved,
highlighting the challenges of comparing shimming methodology: Seemingly minor implementation differences often
have a significant effect on the overall performance of a particular strategy.
Although volumetric mapping methods are thought to be
better suited for large VOIs typical to MRSI, no systematic
studies have been published by the time of this writing that
test this assertion. In addition to the B0 mapping strategy, the
shimming optimization method is crucial for automated and
reliable shimming, and a number of algorithms have been
published and recently compared.123 Improved performance
was found for methods incorporating known constraints on
the maximum available shim strengths and mitigation for
instability; therefore, these types of methods are recommended over simpler unconstrained algorithms.
Adequate hardware is essential for good B0 homogeneity,
and second‐order shim coils are recommended for MRS of
acceptable quality, particularly at 3 T. In addition, adequately
powered shim amplifiers are important to ensure good‐quality data in anatomic regions such as the hippocampus and
frontal brain regions, where there are large susceptibility
gradients.
Our recommendations for second‐order shimming hardware, combined with accurate B0 field mapping and robust
shimming optimization methods, enable the acquisition of
SVS with acceptable spectral quality throughout the brain
at 3 T. However, for whole‐brain MRSI techniques, such
as 3D EPSI, the requirement for homogeneous B0 across
all brain regions simultaneously cannot be achieved with
second‐order shim coils. Figure 6 illustrates how poor B0
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homogeneity results in unusable spectra in the anterior cingulate cortex when using 3D EPSI, therefore restricting the
use of MRS in this region to 2D MRSI or SVS techniques.
Homogeneous B0 across the whole brain is also desirable for
gradient‐echo EPI, and particularly challenging at ultrahigh
field (7 T and above), resulting in the development of a number of novel shimming approaches.124,125 Although these
methods show great potential for improving MRS, at both
low and high field, it is currently unclear which will provide
the best balance among patient comfort, cost, and efficacy.

3.5

|

Data formats and interoperability

The MRS results and data may be exported from the scanner console in the following formats: (1) DICOM MRS, (2)
DICOM secondary capture, and (3) data points stored in a
proprietary format. The DICOM secondary captures (or
“screenshots”) typically store an image of the spectrum and
fit, alongside the voxel location and quantitative measures,
such as metabolite ratios. For MRSI, metabolite maps are
also generally displayed together with relevant MRI scans.
Although secondary captures are essential for rapid clinical interpretation, they do not allow re‐analysis or interactive inspection of the data, which is particularly important
for MRSI. For example, following an initial analysis, it may
become clear that a brain region has an abnormal metabolite
profile that is consistent with a brain tumor; therefore, a re‐
analysis is required using a cancer‐specific metabolite ratio
map with a basis set containing additional metabolites, or it
may be advisable to re‐inspect the spectral quality in crucial
areas.
Storage of the acquired complex MRS data points, either
in the time or frequency domain, is essential to ensure the
extraction of maximal information. Historically, each vendor had 1 or more proprietary formats for exporting raw data
files—primarily for offline analysis with third‐party tools
such as LCModel.32 However, proprietary formats have the
following disadvantages: (1) They require extra time and
computing resources to generate and securely archive, particularly when a hospital contains multiple scanners from different vendors; 2) patient details may not be stored in a way that
allows the reliable identification of files, creating problems
for comparing scans obtained from multiple sites/scanners
and effective de‐identification—often a requirement for clinical trials; and (3) additional burden is placed on researchers
and third‐party software developers to support the file formats, which often change with software updates.
To address these issues, the DICOM standards committee introduced Supplement 49 “Enhanced MR Image
Storage SOP Class” in 2002, which included the “MR
Spectroscopy Information Object Definition” that is suitable for the storage and transfer of MRS data. This allows
MRS data points, and associated localization volume
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and acquisition information, to be archived to the picture
archiving and communication system alongside the MRI,
using a local network and the same protocols and infrastructure in place as in most radiology departments. Therefore,
we recommend the use of the DICOM standard for storage
and network transmission of the MRS data points and analysis results from the scanner, and strongly encourage MR
and picture archiving and communication system vendors
to implement the standard. For SVS, the storage of individual averages is recommended to aid retrospective correction
of frequency and phase instabilities and the identification/
removal of motion‐corrupted averages. Standard DICOM
tags should be used to store all important sequence and
localization information, and the use of private tags for this
information is strongly discouraged, as private tags cannot
be guaranteed to be free from protected health information
and are therefore automatically removed as part of the de‐
identification procedures required for clinical trials.
Although the DICOM‐MRS format is essential for clinical purposes, we also recognize the importance of “raw” data
formats. For instance, the data from each coil element need
to be stored separately for researchers to develop and compare reconstruction methods, and the DICOM format may
not be suitable for these purposes. For these, reconstruction
research–orientated application formats, such as the ISMRM
raw data format, are recommended for data export.126

3.6

|

Reporting

The ideal for using MRS as a clinical biomarker would be the
ability to report tissue metabolite levels fully, quantitatively,
and independent of the scanner type or the pathology under
investigation. In practice, limitations of SNR include the
need for reasonable acquisition times, the need for voxels to
contain mixed tissue types of variable relaxation times, and
the effects of methodological variations due to differences
in scanner software and hardware; these restrict convergence
to the ideal. In addition, there may be reluctance to move
too far away from a specific institutional MRS protocol and
acquire new data that are no longer comparable to historical
studies. Hence, pragmatically, our recommendations balance
limited protocol variability with best practices of acquiring
high‐quality MRS data, avoiding a methodology that leads to
extreme variation in MRS characteristics. Nevertheless, the
appearance of the spectrum may still have characteristics that
depend on the acquisition protocol, and the subsequent data
processing may lead to further differences—all of which may
affect visual or pattern recognition analyses. The most promising clinical applications for MRS have been described,1 but
further work is needed for the development of standardized
MRS biomarkers that enable rigorous and robust multi‐institutional use. Hence, it is essential that key details be provided

in MRS publications to enable appropriate comparisons
among different studies and for meta‐analyses, to better
assess the efficacy of the proposed MRS biomarkers.
At the 2016 ISMRM workshop “MR Spectroscopy: From
Current Best Practice to Latest Frontiers,” attendees were
asked to comment on a set of minimum and recommended
requirements for the reporting of MRS studies. Level 1
requirements were the parameters that are considered the
minimum for proper and correct reporting of MRS studies by more than 80% of the attendees. Parameters that had
between 40% and 80% support as relevant for inclusion in
MRS reporting are ascribed as level 2. A detailed consensus
on MRS reporting is currently being developed for an NMR
in Biomedicine Special Issue (expected publication in late
2019); hence, only the outline of level 1 minimum requirements is included here (Supporting Information Section D) in
relation to our consensus on 1H MRS of the brain.

4 | SUM M ARY AND
CONCLUSIONS
Tables 1, 2, and 3 summarize SVS, 2D MRSI, and analysis/
interpretation recommendations, respectively. To facilitate
greater clinical utility of MRS, we encourage vendors to
implement all recommendations as outlined here. We highlight the following 3 recommendations as being likely to
have the greatest importance for improving routine clinical
MRS and achieving reliable MRS results:
1. Implementation of a robust semi‐LASER protocol to
improve the localization of SVS and MRSI at 3 T;
2. Incorporation of simulated metabolite, lipid, and macromolecular basis sets in spectral analyses for more robust
extraction of the maximum amount of metabolic information available; and
3. Use of optimized algorithms to perform time‐efficient,
robust, and high‐quality automated shimming.123
These highlighted recommendations are all software‐
based and can therefore be implemented on almost all existing clinical scanners, significantly enhancing their MRS
capabilities.
Although we have intentionally restricted the scope of our
recommendations to the most common clinical field strengths
of 1.5 T and 3 T, the same recommendations are also relevant to
ultrahigh field (7 T and above), where reducing CSD and implementing robust shimming present significantly greater challenges.127 Furthermore, a greater number of metabolites can be
detected reliably at ultrahigh field, due to wider chemical shift
dispersion, and the use of comprehensive simulated metabolite
basis sets is required to capture the full metabolite profile.128
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Two‐dimensional MRSI acquisition and preprocessing consensus summary

Aspect

Consensus

Prelocalization method

CSD less than 2% per ppm.
3 T: Semi‐LASER with OVS (preferred) or OVERPRESS with VSS.
1.5 T: Semi‐LASER with OVS (preferred) or PRESS with VSS.

TE and TR

TE as short as possible (typically 30 ms). Longer TEs may be preferred for lactate detection (144
ns or 288 ms) and enhanced lipid suppression.
TR = 1.5 seconds at 1.5 T, 2.0 seconds at 3 T.

Matrix dimensions, nominal voxel
dimensions, and sampling parameters

16 × 16 matrix with 10‐mm in‐plane resolution and 15‐mm slice thickness; 1 average per
phase‐encoding step.
Spectral sampling of 1024 complex data points at 2000‐Hz spectral width at 1.5 T or 3 T.

k‐space sampling and preprocessing

2D phase‐encoded Cartesian sampling over an elliptical or circular k‐space mask.
K‐space zero‐filling (interpolation) to twice the acquired number of points.
Hamming filter.
Reduction of subcutaneous lipid contamination (e.g., Papoulis‐Gerchberg algorithm).

Water‐reference acquisition

Should be acquired where possible. Collect with the same sequence parameters as the water‐suppressed scan, but without water suppression. Typically, to reduce scan time, a lower resolution
scan is acceptable and interpolated following acquisition to match the metabolite resolution.

B0 shimming hardware

Second‐order shim coils with adequately powered amplifiers are recommended at 1.5 T and 3 T.

B0 shimming algorithm

Methods incorporating shim strength limits and instability countermeasures are preferred over
unconstrained approaches.

TABLE 3

Analysis and interpretation consensus summary

Aspect

Consensus

Spectral
preprocessing

Time‐domain apodization (line broadening) and zero‐filling steps should not be applied before spectral fitting, although
may aid visual interpretation. Water reference–based eddy‐current correction42 before fitting is recommended where
possible.

Analysis methods

Methods should be fully automated, performing phasing, chemical shift calibration, and metabolite amplitude estimation
without user intervention.
The flexibility to be able to model typical baseline and linewidth variations is an essential requirement, which may be
achieved using time or frequency‐domain approaches.

Basis set

Methods that incorporate prior knowledge using a basis set are recommended over spectral integration or simple fitting
of independent single peaks.
Metabolite basis sets simulated from known J‐coupling and chemical‐shift values to match the acquisition protocol are
recommended for analysis.
Lipid basis signals should also be incorporated for tumor analysis and macromolecule signals for short‐TE (< 80 ms)
analyses.

Quality assessment

Single‐peak metabolite and, where available, water linewidths should be measured at half height (FWHM) as part of an
automated analysis pipeline.
Metabolite or water linewidths less than 0.1 ppm are required for accurate analysis, and a metabolite SNR greater than 3
is the minimum criterion for determining the presence of a singlet.
Visual assessment of spectral and fit quality is recommended, based on the combined display of the phased spectrum, fit,
estimated baseline, and fit residual.

Consensus on appropriate experimental methodology is an evolving process, and we emphasize that this
paper should not represent the final word on the topic.
Our intention is to provide an assessment of the current
state‐of‐the‐art and recommend improvements to MRS
methodology and standardization, with a strong focus on

clinical applications. However, variety is essential for fruitful developments of new and alternative methods, yielding
the clinical workhorses of the future. A current initiative
will produce a special issue that will expand on this paper
with a greater focus on ultrahigh‐field MRS and more
novel methods.
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In conclusion, a large body of research demonstrates
that (1) robust, high‐quality MRS data may be acquired
with the hardware available on current clinical MR systems; and (2) many technical challenges of performing
clinically useful SVS and MRSI at 1.5 T and 3 T can be
overcome with software improvements applied to current
scanner hardware. In this consensus paper, a series of
methodological recommendations have been made to provide a degree of standardization and equivalency of methodology across all scanner platforms, and guidelines have
been drawn up on the current best practices for clinical
MRS.
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FIGURE S1 A selection of example spectra demonstrating the following features: good shimming (A), acceptable
shimming (B), poor shimming and water suppression (C),
out‐of‐volume lipid contamination (D), “ghost” artifact (E),
and very poor shimming and water suppression (F). Further
examples of poor spectra may be found in Refs 43 and 129
FIGURE S2 Single‐voxel spectroscopy planning with moderate CSD. Incorrect (A) and improved (C) voxel planning
by reversal of the gradient polarity in the left–right direction;
corresponding spectra are shown in (B) and (D). Lipid and
metabolite excitation regions are shown in cream and orange,
respectively
FIGURE S3 The effect of TR on the SNR per unit time due
to T1 saturation relative to that at TR = 6000 ms. On average,
across the 4 metabolite curves shown, the maximum SNR
per unit time is close to 1500 ms at 1.5 T and 2000 ms at 3
T. The metabolite T1 values used are the average values from
different normal brain regions acquired with exactly the same
acquisition and processing protocols at both 1.5 T and 3 T:
tCho = 1103/1290 ms; tCr = 1232/1375 ms; and tNAA =
1303/1482 ms.130 A lactate T1 of 2000 ms at 3 T for high‐
grade gliomas was used,131 and this value scaled to 1754 ms
for 1.5 T using a factor of 1.14, the average ratio of the normal‐tissue metabolite T1 values at the 2 field strengths
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FIGURE S4 Effect of T1 saturation on tissue water signals
and main metabolite signals and clinically relevant metabolite ratios. A TR of 6000 ms is required to maintain the
signals shown within 95% of their unsaturated values. At
1.5 T, the T1 values of 3 key metabolites and gray matter
are similar, and although they are more dispersed at 3 T,
they have less variability than that for tissue‐water T1. Apart
from lactate, the saturation curves for signal from pathological tissues are not shown, but pathological tissue with
increased water content could have a water‐saturation curve
that is similar to that of lactate (see text for discussion on
metabolite T1 values in pathological tissue). Tissue‐water
T1 relaxation times used for 1.5 T/3 T calculations were
white matter = 650/840 ms; gray matter = 1200/1600
ms.132 Metabolite T1 values were those used in Supporting
Information Figure S3
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